ArticleJournal of cardiac failure - intersections2026
Life-Space Mobility in Heart Failure With Preserved Ejection Fraction.
Article in Journal of cardiac failure - intersections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Background: Life-space mobility quantifies an individual's movement within their environment, ranging from one's bedroom to outside of one's geographic region. This makes life-space mobility an appealing yet understudied summary evaluation that can effectively integrate multiple health domains inclusive of conditions that are prevalent in heart failure with preserved ejection fraction (HFpEF). Whether life-space mobility is associated with adverse outcomes among patients with HFpEF who are ambulatory is unknown. Methods: We examined 175 consecutive patients with HFpEF seen at the Weill Cornell Medicine HFpEF program (November 2018 through March 2022). Life-space mobility was quantified via the Life-Space Assessment (LSA) and a simplified version of the LSA. The Kansas City Cardiomyopathy Questionnaire-12 and EuroQol 5-Dimension 5-level were used to examine the quality of life. The primary outcome was a 12-month composite of all-cause mortality and hospitalization. A Cox proportional-hazard model was used to examine the association between life-space mobility and the primary outcome, adjusting for race and the Meta-Analysis Global Group in Chronic Heart Failure score. Results: The median age was 76.8 years (interquartile range, 69.7-84.6 years). Most patients were female (67.4%) and of White race (65.1%). Those with low life-space mobility (based on both the LSA and simplified LSA) reported a worse quality of life (as measured by the Kansas City Cardiomyopathy Questionnaire-12 and EuroQol 5-Dimension 5-level). In addition, low life-space mobility (based on both the LSA and simplified LSA) was independently associated with all-cause hospitalization at 12-months in a fully adjusted model (LSA: hazard ratio, 2.41; 95% confidence interval, 1.23-4.69, Conclusion: Among adults with HFpEF, life-space mobility tracks with multiple health deficits, parallels quality of life, and is associated with adverse clinical outcomes. The LSA and simplified LSA provide comparable prognostic information, suggesting that either could serve as a summary score of health and prognostic indicator among HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.